Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04133-z
Abstract: Eculizumab is effective in managing patients with paroxysmal nocturnal hemoglobinuria (PNH). In South Korea, the financial support for eculizumab therapy is extended by the National Health Insurance Services (NHIS) only to patients with high-risk PNH… read more here.
Keywords: group; paroxysmal nocturnal; eculizumab; nocturnal hemoglobinuria ... See more keywords
Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis
Sign Up to like & getrecommendations! Published in 2023 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofad159
Abstract: Abstract Eculizumab, a recombinant humanized monoclonal antibody (mAb), is used for the treatment of patients (both adults and children) with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This mAb binds to complement protein 5… read more here.
Keywords: cryptococcosis following; following eculizumab; eculizumab therapy; pathogenesis ... See more keywords
Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2021.733042
Abstract: Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS). However, there are few studies evaluating eculizumab therapy among children… read more here.
Keywords: uremic syndrome; among children; hemolytic uremic; therapy ... See more keywords